BIOARCTIC AB

Their core work

BioArctic is a Swedish biotech SME specializing in neurodegenerative diseases, with deep expertise in Parkinson's disease and spinal cord injury. They develop diagnostic biomarkers and therapeutic approaches targeting protein misfolding — particularly alpha-synuclein, a key protein implicated in Parkinson's. Their work spans from validating clinical biomarkers to developing advanced molecular imaging tools (PET tracers) that can visualize disease progression in living patients, bridging the gap between laboratory research and clinical diagnostics.

What they specialise in

How they've shifted over time

BioArctic's early H2020 work (2015-2016) focused on two distinct therapeutic areas: regenerative medicine for spinal cord injury (their largest funded project) and clinical biomarker validation for Parkinson's disease. By 2018, their focus narrowed and deepened toward molecular imaging of neurodegeneration — specifically PET imaging of alpha-synuclein — suggesting a strategic shift from broad neuroscience toward precision diagnostics for Parkinson's disease.

BioArctic is moving toward advanced molecular imaging for neurodegenerative diseases, positioning itself at the intersection of radiopharmaceuticals and Parkinson's diagnostics — a high-growth area as precision medicine expands into neurology.

How they like to work

BioArctic leans toward leading projects — coordinating 2 out of 3 H2020 initiatives — which is notable for an SME. With 22 unique partners across 10 countries, they build broad international consortia rather than relying on a narrow set of repeat collaborators. This suggests an organization comfortable driving research agendas and managing multi-country partnerships, making them a credible consortium lead for future proposals despite their small company size.

BioArctic has collaborated with 22 distinct partners across 10 countries, reflecting a wide European network for a biotech SME. Their partnerships span both clinical research institutions and academic groups, with no visible geographic concentration beyond their Swedish base.

What sets them apart

BioArctic is one of few European biotech SMEs with hands-on expertise in both alpha-synuclein biology and PET radiotracer development for neurodegeneration — two fields that rarely overlap in a single small company. Their dual track record as project coordinator and their SME Instrument Phase 1 award signal strong commercial ambition alongside scientific depth. For consortium builders targeting Parkinson's diagnostics or neurodegenerative disease imaging, BioArctic brings both domain credibility and a proven ability to lead EU-funded projects.

Highlights from their portfolio

• SC0806
  Largest funded project (EUR 653K) and coordinated by BioArctic — an ambitious regenerative therapy for complete spinal cord injury involving surgical implantation.
• PET-AlphaSy
  Represents BioArctic's strategic pivot into molecular imaging, combining radiopharmaceutical science with Parkinson's disease research in an MSCA training network.
• Biomarkers for PD
  SME Instrument Phase 1 project — signals that BioArctic was actively seeking to commercialize Parkinson's biomarker technology.